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Clinical trials are being conducted to evaluate the safety and
efﬁcacy of hematopoietic stem cell transplantation (HSCT) as a
therapy for patients with severe, refractory systemic lupus ery-
thematosus (SLE). Nurses coordinating the care of patients receiv-
ing HSCT may be unfamiliar with aggressive systemic autoim-
mune diseases, such as refractory SLE. The presentations of SLE
can include nephrotoxicity, pulmonary toxicity, permanent alter-
ations in mobility, cognitive impairment, blindness, chronic pain,
as well as the many complications of long term immunosuppressive
therapy. Such problems present intense and unanticipated chal-
lenges for the medical team and affect many aspects of a patient’s
physical and emotional well being.
The purpose of this project is to share our experience using a
nurse led Collaborative Care Model. The model highlights impli-
cations for the multidisciplinary care team, nursing education and
support, and resource utilization. It also provides a template for
utilizing patient resources not previously identiﬁed.
Complex and serious problems are an inherent part of SLE and
present different dynamics and chronicity when compared to typ-
ical hematology/oncology HSCT patients. Therefore, a care man-
agement model promoting collaborative relationships within a
multidisciplinary team was essential. The nursing led team, which
included research nurses, clinical nurses, clinical nurse specialists,
nurse managers, and nurse practitioners, was instrumental in the
Collaborative Care Model.
At our research center, this model was utilized to coordinate the
HSCT care of 8 patients with severe SLE. The research nurse
functioned as team coordinator, maintaining constant communi-
cation between the patient, transplant team, rheumatology service
and other specialties involved in the plan of care. The research
nurse ensured protocol compliance, ongoing staff education and
protection of human subjects. Interdisciplinary meetings were held
weekly to provide a forum for discussion and dissemination of
information. The model facilitated a partnership between nurses,
medical specialists and ﬁnancial, social, and community services
which ensured timely access to resources and support.
As the role of HSCT is evaluated in additional non-malignant
disorders, nurses will be faced with new challenges and unfamiliar
patient populations. HSCT centers may ﬁnd our Collaborative
Care Model a way to effectively utilize resources and manage
complex patients.
376
TREATMENT OF ACUTE GRAFT VS. HOST DISEASE AFTER UNRELATED
DONOR UMBILICAL CORD BLOOD TRANSPLANTATION IN PEDIATRIC
PATIENTS
Baker, E.J.2, Frey, M.A.2, Kurtzberg, J.2 1Duke University Hospital,
Durham, NC; 2The Duke Pediatric Blood and Marrow Transplant
Program, Durham, NC.
Unrelated donor umbilical cord blood (UCB) has been shown to
be an important source of hematopoietic stem cells for transplan-
tation in patients unable to ﬁnd a fully matched related or unre-
lated donor. UCB is readily available and can be used with partial
HLA matching allowing access to donors for transplantation for
the many patients who will never ﬁnd or who do not have time to
ﬁnd a perfectly matched bone marrow donor. Over the past 13
years, our program has performed 600 UCBT in pediatric pa-
tients with hematological malignancies, bone marrow failure syn-
dromes, immunodeﬁciency syndromes, hemoglobinopathies and
inborn errors of metabolism. In two thirds of these transplants,
donor/recipient pairs were matched at 4/6 HLA loci. Grades II-IV
acute graft-versus-host disease (GvHD) occured in approximately
35-40% of patients underdoing UCBT despite prophylactic ther-
apy. We have utilized cyclosporine/methylprednisolone or, more
recently cyclosporine/cellcept (MMF) for GvHD prophylaxis.
Many patients experience erythroderma with fever between days
11-25 post transplant, before neutrophil engraftment which may
represent engraftment syndrome or early GvHD. We have treated
this syndrome with a pulse of methylprednisolone (500mg/m2/
dose IV q12h X 4 doses for patients receiving conventional dose
steroids for GvHD prophylaxis, or 1-2mg/kg/day divided BID for
those on MMF). Responding patients taper steroids over the next
few weeks. Those that don’t respond or who experience rash or
diarrhea after initial steroid taper clearly have acute GvHD and are
switched to FK-506 with dacluzimab. Most patients are controlled
on this regimen which is then slowly weaned over the next 3-4
months. For the small number of patients (5%) not responding
to this therapy, inﬂiximab is added. For those failing inﬂiximab,
alternative therapies are pursued. GvHD after UCBT is different
than that after bone marrow transplantation in that rashes are
milder and progression to the GI tract is rarer and more indolent.
Liver GvHD is rare. This presentation will discuss the clinical
presentations, treatment and overall outcomes of pediatric patients
undergoing UCBT developing acute GvHD.
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Approximately 20% of patients undergoing unrelated donor um-
bilical cord blood transplantation (UCBT) with a single cord blood
unit, will fail to engraft. The causes for graft failure include host
immunological rejection with or without autologous reconstitu-
tion, infection and relapse. Over the past 13 years, the Pediatric
Blood and Marrow Transplant Program at Duke has transplanted
600 Pediatric patients with malignant diagnoses, lysosomal stor-
age diseases, hemoglobinopathies, congenital marrow failure syn-
dromes and congenital immunodeﬁciency syndromes with unre-
lated donor UCB. Thirty of these patients have experienced graft
failure and have been treated with a second UCBT as salvage
therapy. Median age of the group was 5 years (range 1-20 years),
73% were male, 40% non-Caucasian and 43% had malignant
diagnoses. All but 2 patients received myeloablative therapy as
preparation for their ﬁrst transplant. The median cell dose for the
ﬁrst transplant was 4.410e7/kg (range 0.99-21.25). 60% of the
ﬁrst transplants were matched at 4/6 HLA loci while 32% were
matched at 5/6 loci. Reasons for graft failure after transplant #1
were persistent leukemic disease (n1), autologous recovery
(n12) and graft rejection with aplasia (n17). All patients were
prepared for their second transplant with reduced intensity therapy
including cyclosphosphamide 30mg/kg/dose daily x 2, ATG (horse
or rabbit) x 3 days /- ﬂudarabine, campath or low dose TBI. Cell
doses were similar to the ﬁrst transplant and HLA disparity slightly
greater. All patients were supported with G-CSF mobilized, irra-
diated granulocytes during their second aplasia. Twenty patients
(66%) engrafted with donor cells after a second (n18) or third
(n2) transplant. Two patients died before engraftment, 1 re-
mained in relapse, and the others experienced second autologous
reconstitution. Eleven patients (35%) remain durably engrafted,
surviving long term with a median follow-up of 2 years (range
1-7 years). We conclude that a second UCBT after primary graft
failure offers a chance for long term survival in a signiﬁcant num-
ber of patients.
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AN EXPLORATORY ANALYSIS OF SYMPTOM EXPERIENCE AT DAYS 30
AND 100 FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION (AHSCT)
Bevans, M.F.1, Mitchell, S.A.1, Marden, S.1 1Clinical Center, National
Institutes of Health, Bethesda, MD.
Background: Despite advances in AHSCT treatment and sup-
portive care, post-transplant complications are common and char-
acterization of patients’ symptom experience is needed before de-
veloping symptom management strategies. Purpose: Using the
Symptom Management Model1 as a theoretical foundation, this
exploratory analysis examined patients’ symptom perception and
symptom evaluation in the early period following AHSCT.Meth-
ods: Data were collected as part of a prospective study examining
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